Endocrine & Metabolic PGx Panel

The Endocrine & Metabolic PGx Panel is intended for individuals receiving endocrine or metabolic therapies who may benefit from personalized pharmacogenetic-guided medication management. This panel evaluates clinically relevant genetic variants associated with drug metabolism, efficacy, and safety for medications commonly used in endocrine and metabolic conditions, including oral contraceptives, diabetes therapies, and other metabolic treatments. Pharmacogenetic testing may help guide medication selection and dosing, identify increased risks of adverse drug reactions such as thrombosis or hypoglycemia, and support safer, more effective individualized treatment strategies. Upon completion of testing, patients receive an interpretive pharmacogenetic report and certificate summarizing clinically relevant results and medication-related findings to support ongoing care and future treatment decisions.

Turnaround Time: 3-7 business days
Preferred specimens: Saliva
Alternate specimens: Buccal Swab

Testing Kit Request Form

Cardio-kidney-metabolic (CKM) conditions often require complex medication regimens, with patients frequently experiencing variability in drug response. Genetic differences in drug-metabolizing enzymes, transporters, and target pathways can influence treatment outcomes for cardiovascular disease, chronic kidney disease, and metabolic disorders. Pharmacogenomic testing enables more personalized prescribing, helping to improve efficacy, reduce adverse drug reactions, and support better long-term disease management.